Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the growth and viral capsid antigen expression of Epstein-Barr virus-associated tumor (B-95-8) cells transplanted to nude mice.
When persistently Epstein-Barr virus (EBV)-infected lymphoblastoid (B-95-8) cells were transplanted subcutaneously or intracerebrally to nude mice of either BALB/c or NIH background, tumors developed, and the tumor cells spontaneously expressed viral capsid antigen (VCA). This model was used to evaluate the in vivo anti-EBV activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), a highly potent and selective antiherpes agent, which was recently shown to inhibit several parameters of EBV infection in vitro. When administered intraperitoneally at 200 mg/kg/day for 4 weeks, or 500 mg/kg/day for 2 weeks, starting immediately after B-95-8 cell inoculation, BVDU effectively reduced tumor growth and VCA expression of either subcutaneously or intracerebrally inoculated B-95-8 cells.
Zhang
Z X
ZX
Dong
W P
WP
Chen
H S
HS
Xu
Z G
ZG
Zhang
Z H
ZH
Liu
S M
SM
De Clercq
E
E
D000818:Animals; D000956:Antigens, Viral / Q000235:genetics* / Q000627:therapeutic use; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002213:Capsid / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D005260:Female; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000235:genetics; D008214:Lymphocytes / Q000382:microbiology; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014412:Tumor Virus Infections / Q000235:genetics*
D000956:Antigens, Viral; C020235:brivudine; D001973:Bromodeoxyuridine